Related Experiment Video

Updated: Aug 20, 2026

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody
07:36

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

Promises and challenges of targeting Bcl-2 anti-apoptotic proteins for cancer therapy

Jason O'Neill1, Michael Manion, Pam Schwartz

  • 1Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue N., D2-190, PO Box 19024, Seattle, Washington 98109-1024, USA.

Biochimica Et Biophysica Acta
|December 9, 2004
PubMed

Insights

Targeting BCL-2 proteins can kill cancer cells resistant to chemotherapy. New small molecules show promise for cancer drug development, despite challenges in understanding BCL-2

Area of Science:

  • Oncology
  • Molecular Biology
  • Drug Discovery

Background:

  • Elevated BCL-2 and related proteins confer resistance to cytotoxic chemotherapy in cancer cells.
  • Antisense oligodeoxynucleotides and small molecule ligands targeting BCL-2/BCL-XL offer direct cytotoxicity or synergy with standard agents.
  • These targeted agents may exhibit selectivity for tumor cells.

Purpose of the Study:

  • To explore the challenges and potential of BCL-2-targeted therapeutics in cancer treatment.
  • To investigate the cytotoxic mechanisms and identify surrogate markers for BCL-2 function.
  • To evaluate the utility of newly available small molecules targeting BCL-2/BCL-XL in preclinical settings.

Main Methods:

  • Review of existing literature on BCL-2 function and targeted therapies.
  • Analysis of challenges in rational drug discovery for BCL-2-related therapeutics.
  • Preclinical evaluation of small molecule ligands for BCL-2 and BCL-XL.

Main Results:

  • BCL-2 family proteins are key regulators of apoptosis and are often dysregulated in cancer, leading to chemoresistance.
  • Small molecule inhibitors of BCL-2 and BCL-XL are emerging as promising therapeutic strategies.
  • Significant obstacles remain in understanding BCL-2 molecular functions and validating drug targets.

Conclusions:

  • Despite challenges in drug development, small molecules targeting BCL-2/BCL-XL represent a promising avenue for overcoming cancer cell resistance.
  • Further basic research is crucial for optimizing strategies to disrupt BCL-2 survival functions and improve cancer therapy.
  • Preclinical studies with novel BCL-2-targeting agents are expected to provide valuable insights into their therapeutic potential.

More Related Videos

In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research08:53

In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research

Published on: September 16, 2019

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Cellular Injury V: Apoptosis and Autophagy01:22

Cellular Injury V: Apoptosis and Autophagy

Cells respond to damage and stress through highly coordinated processes that decide whether they survive or undergo controlled self-destruction. Two major pathways involved in this regulation are apoptosis, a type of programmed cell death, and autophagy, a survival mechanism that helps cells adapt to adverse conditions.ApoptosisApoptosis removes aged or injured cells to maintain tissue balance. During this process, the cell shrinks, chromatin condenses and fragments, and membrane-bound...